retatrutide trial weight loss results Triple hormone receptor agonist for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a Retatrutide approval: FDA status, clinical
Description
Glucagon Receptor Agonism (GCGR) The inclusion of the Glucagon receptor is what distinguishes Retatrutide from Tirzepatide
The Phase 3 trial data supports the Phase 2 trial data, which is a huge relief
Ross DS, Litofsky D, Ain KB, Bigos T, Brierley JD, Cooper DS, Haugen BR, Jonklaas J, Ladenson PW, Magner J, Robbins J, Skarulis MC, Steward DL, Maxon HR, Sherman SI
In fact, research has shown that you can decrease your risk of developing type 2 diabetes mellitus by 50% by losing just 5% of your body weight
Im six feet tall and fluctuate between 215 and 220 pounds
